株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:パイプライン分析

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 303576
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.29円で換算しております。
Back to Top
バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:パイプライン分析 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2016
出版日: 2016年12月14日 ページ情報: 英文 45 Pages
概要

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症とは、黄色ブドウ球菌(Staphylococcus aureus)という細菌が抗生物質バンコマイシンに対する薬剤耐性を獲得することにより発症する疾患です。主なリスク要因には、強力な抗生物質を不適切な方法で摂取すること(により細菌が抗生物質への耐性を強めること)や、免疫系の弱体化、長期間の入院生活などが含まれています。主な症状として、高熱や悪寒、せき、胸痛、呼吸困難、頻脈などが挙げられます。

当レポートでは、世界各国でのバンコマイシン耐性黄色ブドウ球菌感染症 (以下VSRA) 治療向けパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や治験の各段階にある製品、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症の概要

治療薬の開発

  • 概要
  • パイプライン製品の比較分析

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:企業で開発中の治療薬

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:大学/機関で研究中の治療薬

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:企業で開発中の製品

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:大学/機関で研究中の製品

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症の治療薬開発に従事している企業

  • CrystalGenomics, Inc.
  • Debiopharm International SA
  • iNtRON Biotechnology Inc.
  • Wockhardt Limited

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:最近のパイプライン動向

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:休止中のプロジェクト

バンコマイシン耐性黄色ブドウ球菌 (VRSA) 感染症:開発が中止された製品

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8812IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2016, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline landscape.

Vancomycin resistant staphylococcus infection is a condition caused by bacteria (germs). This infection occurs when bacteria, called Staphylococcus aureus or Staph, becomes resistant (not killed) to the antibiotic medicine vancomycin. Risk factors include taking strong antibiotics the wrong way may cause the bacteria to develop resistance to the antibiotics, weak immune system and staying in the hospital too long. Symptoms include fever, chills, cough, chest pain, trouble breathing, and a fast heartbeat.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections.

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Overview
  • Therapeutics Development
    • Pipeline Products for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview
    • Pipeline Products for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Comparative Analysis
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics under Development by Companies
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics under Investigation by Universities/Institutes
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Products under Development by Companies
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Products under Investigation by Universities/Institutes
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved in Therapeutics Development
    • CrystalGenomics Inc
    • Debiopharm International SA
    • e-Therapeutics Plc
    • iNtRON Biotechnology Inc
    • Wockhardt Ltd
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (miconazole nitrate + nisin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-400549 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Debio-1450 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Epidermicin NI-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAL-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Bacterial Cell Wall for MRSA and VRSA Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-2078 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WCK-4086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H2 2016
  • Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics Inc, H2 2016
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Debiopharm International SA, H2 2016
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by e-Therapeutics Plc, H2 2016
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by iNtRON Biotechnology Inc, H2 2016
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, H2 2016
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, H2 2016
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by 21st Century Therapeutics Inc, H2 2016

List of Figures

  • Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H2 2016
  • Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top